BioFlyte Raises $1.25M in Seed Funding
Summary
The company intends to use the funds to accelerate development of its fieldable mass spectrometer that enables miniaturized, low-cost, and low-power detection and identification of airborne microbes and toxins in real-time. Led by Charles Call, PhD, cofounder and Chief Executive Officer, BioFlyte commercializes a new class of fieldable biological threat collection, detection, and identification solutions. The advanced filter design incorporated into the z750 has extensively validated sample extraction protocols, and is compatible with PCR, immunoassay, and fieldable mass spec instruments, as well as analytical methods associated with laboratory confirmation. The company also announced that Dr. Wayne Bryden and Mr. David Seldin have joined the company’s Board of Directors. Dr Bryden is a co-founder and CEO of Zeteo Tech and previously served as the Chief Science Officer at ICx Technologies (acquired by FLIR Systems) and as a DARPA program manager after many years of research at the John Hopkins University’s Applied Physics Laboratory.